VA Connecticut Healthcare System

Summary

VA Connecticut Healthcare System is a medical facility located in West Haven, Connecticut. This center is recognized for care of Lung Cancer, Post-Traumatic Stress Disorder, Alcohol-Related Intimate Partner Violence, Schizophrenia, Psychotic Episodes and other specialties. VA Connecticut Healthcare System is involved with conducting 280 clinical trials across 411 conditions. There are 32 research doctors associated with this hospital, such as Herta H. Chao, Mohini Ranganathan, MD, Deepak C. D'Souza, M.D., and Joao P. De Aquino, M.D..

Top PIs

Clinical Trials running at VA Connecticut Healthcare System

Lung Cancer

Prostate Cancer

Post-Traumatic Stress Disorder

Bladder Cancer

Non-Small Cell Lung Cancer

Chronic Pain

Cancer

Acute Myeloid Leukemia

Colorectal Cancer

Depression

Chemotherapy + Immunotherapy vs. Immunotherapy

for Advanced Lung Cancer

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.

Recruiting

2 awards

Phase 3

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Immunotherapy

for Lung Cancer

This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.

Recruiting

1 award

Phase 2